大行評級|建銀國際:上調藥明康德目標價至45港元 維持“跑贏大市”評級
建銀國際發表報吿指出,美國食品藥監局今年上半年批准14種小分子新藥,當中3種由藥明康德生產,再次印證公司具競爭力的價格快速提供最優質服務的長期策略。管理層預期,下半年將有3至5種小分子商業專案獲批,與去年下半年及今年上半年的速度一致。該行預期,藥明康德的TIDES業務加速,將成為公司未來主要動力。此外,該行認為美國參議院尚未安排就《生物安全法案》立法草案作出投票,預期有關法案或不大可能在今年底前獲得通過。該行預期,藥明康德下半年將維持相似的步伐,由於TIDES業務發展較快,將行將公司2026至2032年長期銷售增長率預測,由4.4%上調至6.5%;每股盈利平均上調5.7%,對其目標價由40港元升至45港元,維持“跑贏大市”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.